Migrane ppt
-
Upload
deepak-sarangi -
Category
Education
-
view
346 -
download
1
Transcript of Migrane ppt
![Page 1: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/1.jpg)
MIGRAINE
A Concise Presentation
By
Mr. Deepak Sarangi M.Pharm
![Page 2: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/2.jpg)
2
CONTENTS: Introduction Definition Migraine triggers Phases Classification Pathophysiology Diagnosis Goals for treatment Management Guidelines Summary of prevention Conclusion References
![Page 3: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/3.jpg)
3
INTRODUCTION: Migraine is one of the common causes of
recurrent headaches.
According to IHS, migraine constitutes 16% of primary headaches.
Migraine afflicts 10-20% of the general population.
In India, 15-20% of people suffer from migraine.
Migraine is under diagnosed and undertreated.
![Page 4: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/4.jpg)
4
“Migraine is a familial disorder characterized by recurrent attacks of headache widely variable in intensity, frequency and duration. Attacks are commonly unilateral and are usually associated with anorexia, nausea and vomiting”.
DEFINITION:
![Page 5: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/5.jpg)
5
MIGRAINE TRIGGERS: Disturbed sleep pattern Hormonal changes Drugs Physical exertion Visual stimuli Auditory stimuli Olfactory stimuli Weather changes Hunger Psychological factors
![Page 6: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/6.jpg)
6
PHASES:
Prodrome
Aura
Headache
Postdrome
![Page 7: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/7.jpg)
7
PRODROME: Vague premonitory symptoms that begin
from 12 to 36 hours before the aura and headache.
Symptoms: Yawning Excitation Depression Lethargy Craving or distaste for various foods
Duration: 15 to 20 min.
![Page 8: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/8.jpg)
8
AURA:
Aura is a warning or signal before onset of headache.
Symptoms:Flashing of lightsZig-zag linesDifficulty in focussing
Duration : 15-30 min.
![Page 9: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/9.jpg)
9
HEADACHE: Headache is generally unilateral and is
associated with SYMPTOMS like: 1. Anorexia2. Nausea3. Vomiting 4. Photophobia5. Phonophobia6.Tinnitus
Duration: 4-72 hrs.
![Page 10: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/10.jpg)
10
POSTDROME:Following headache, patient complains of - Fatigue Depression Severe exhaustion Some patients feel unusually fresh
Duration: Few hours or up to 2 days.
![Page 11: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/11.jpg)
11
CLASSIFICATION:According to Headache Classification
Committee of the International
Headache Society, Migraine has been
classified as: Migraine without aura (common migraine) Migraine with aura (classic migraine) Complicated migraine
![Page 12: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/12.jpg)
12
PATHOPHYSIOLOGY:
VASCULAR THEORY:-o Intracranial/Extracranial blood vessel vasodilation –
headache.o Intracerebral blood vessel vasoconstriction – aura.
SEROTONIN THEORY:-
o Decreased serotonin levels linked to migraine.o Specific serotonin receptors found in blood vessels of
brain.
![Page 13: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/13.jpg)
13
Release of Neurotransmitter
Arterial Activation
Worsening of Pain
![Page 14: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/14.jpg)
14
DIAGNOSIS: Medical History Headache diary Migraine triggers Investigations
EEGCT BrainMRI
![Page 15: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/15.jpg)
15
GOALS FOR TREATMENT: Establish diagnosis. Educate patient. Discuss findings. Establish reasonable expectations. Involve patient in decision. Encourage patient to avoid triggers. Choose the best treatment. Create treatment plan.
![Page 16: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/16.jpg)
16
LONGTERM TREATMENT: Reducing the attack frequency and severity. Avoiding escalation of headache medication. Educating and enabling the patient to manage
the disorder. Improving the patient’s quality of life.
![Page 17: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/17.jpg)
17
MANAGEMENT: Non-pharmacological treatment:-
Identification of triggers Meditation Relaxation training Psychotherapy
Pharmacotherapy:- Abortive therapy Preventive therapy
![Page 18: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/18.jpg)
18
ABORTIVE THERAPYNon-specific treatment:
Drug Dose Route
Aspirin 500-650 mg Oral
Paracetamol 500 mg-4 g Oral
Ibuprofen 200- 300 mg Oral
Diclofenac 50-100 mg Oral/IM
Naproxen 500-750 mg Oral
![Page 19: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/19.jpg)
19
o
SPECIFIC TREATMENT:
Drug Dose Route
Ergot alkaloidsErgotamine 1-2 mg/d; max-6
g/dOral
Dihydroergotamine 0.75-1 mg SC
5-HT receptor agonistsSumatriptan 25-300 mg
6 mgOrallySC
Rizatriptan 10 mg Orally
![Page 20: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/20.jpg)
20
PREVENTIVE THERAPY:Drugs Dose (mg/d)
1. Betablockers Propranolol 40-320
2. Calcium Channel Blockers Flunarizine Verapamil
10-20120-480
3. TCAs Amitriptyline 10-20
4. SSRIs Fluoxetine 20-60
![Page 21: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/21.jpg)
21
GUIDELINES: Migraine significantly interferes with patient’s daily
routine, despite acute treatment.
Acute medications ineffective, intolerable, or overused.
Frequent headache.
Uncommon migraine conditions.
Cost considerations.
Patient preference.
![Page 22: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/22.jpg)
22
SUMMARY OF PREVENTION: Use preventive medications when needed. Treat long enough. Avoid acute medications overuse. Take coexisting conditions into account. Use drug with best efficacy for individual
patient.
![Page 23: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/23.jpg)
23
CONCLUSION: It is more common in adults than children and in women
than men. While researchers have some idea of what happens within the brain during migraine attacks, much remains to be discovered about its underlying causes and mechanisms.
In addition, treatment focuses on avoiding those things that seem to trigger attacks, identifying drugs that prevent or reduce the severity of attacks and drugs that reduce the intense pain of a severe attack.
The good news is that several classes of drugs are effective for different kinds of migraine and most migraine sufferers can work with their doctor to minimize migraine's effects.
![Page 24: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/24.jpg)
24
REFERENCES: Headache Classification Committee The International
Classification of Headache Disorders. 2nd edition. Cephalalgia. 2004;24:1–160.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001;41:646–657.
Radat F, Swendsen J. Psychiatric comorbidity in migraine: A review. Cephalalgia. 2004;25:165–178.
Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life and depression: A population-based case control study. Neurology. 2000;55:629–35.
![Page 25: Migrane ppt](https://reader033.fdocuments.us/reader033/viewer/2022051503/5879b9851a28ab6b2c8b77bf/html5/thumbnails/25.jpg)
25
THANKS for viewing the ppt
For more ppts on pharma related topics plz
contact [email protected]
Or find me at following linkwww.facebook.com/sarangi.dipu